Lipocine Inc (LPCN)
NASDAQ:LPCN
Want to see LPCN full AI Analyst Report?
Top Page
Lipocine
(NASDAQ:LPCN)
Select Model
Select Model
Rating:44Neutral
Price Target:
$2.00
▼(-31.51% Downside)
Action:Reiterated
Date:05/20/26
The score is primarily weighed down by weak financial performance (ongoing losses and cash burn) and bearish technicals (price below major moving averages with negative MACD). A debt-free balance sheet provides some stability, while corporate updates are mixed due to the Phase 3 primary-endpoint miss despite ongoing program visibility.
Positive Factors
Debt-free balance sheet
Lipocine's lack of meaningful debt and rising equity provide durable financial flexibility, lowering solvency risk and extending runway versus peers. This structural strength supports continued R&D or partnership options without immediate debt servicing pressure, improving strategic optionality.
Negative Factors
Phase 3 primary endpoint miss
The Phase 3 failure on its primary endpoint is a structural setback for LPCN 1154, reducing near-term approval probability and commercial prospects. It necessitates further validation or narrower indications, increasing development time, cost, and uncertainty around program value and market entry.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
Lipocine's lack of meaningful debt and rising equity provide durable financial flexibility, lowering solvency risk and extending runway versus peers. This structural strength supports continued R&D or partnership options without immediate debt servicing pressure, improving strategic optionality.
Read all positive factors
Lipocine (LPCN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$18.63M
Dividend YieldN/A
Average Volume (3M)247.10K
Price to Earnings (P/E)―
Beta (1Y)0.48
Revenue Growth-45.52%
EPS Growth-94.82%
CountryUS
Employees16
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.96
Shares Outstanding8,244,253
10 Day Avg. Volume96,659
30 Day Avg. Volume247,099
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)3.02
Price to Sales (P/S)22.14
P/FCF Ratio-4.48
Enterprise Value/Market Cap0.43
Enterprise Value/Revenue4.05
Enterprise Value/Gross Profit-49.29
Enterprise Value/Ebitda-0.67
Forecast
1Y Price Target
$6.00Price Target Upside105.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.93
Revenue Forecast (FY)$650.00K
Lipocine Business Overview & Revenue Model
Company Description
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery sol...
How the Company Makes Money
null...
Lipocine Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.00M | 1.98M | 11.20M | -2.85M | 500.00K | 16.14M |
| Gross Profit | -164.35K | -6.61M | 11.20M | -13.03M | -8.06M | 8.48M |
| EBITDA | -12.07M | -10.31M | -1.11M | -17.90M | -10.72M | -430.53K |
| Net Income | -11.43M | -9.63M | 8.35K | -16.35M | -10.76M | -634.40K |
Balance Sheet | ||||||
| Total Assets | 25.36M | 17.01M | 22.51M | 23.00M | 37.54M | 52.48M |
| Cash, Cash Equivalents and Short-Term Investments | 24.73M | 14.93M | 21.63M | 22.04M | 32.53M | 44.62M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.31M |
| Total Liabilities | 2.53M | 2.53M | 1.51M | 2.63M | 1.91M | 6.91M |
| Stockholders Equity | 22.83M | 14.48M | 21.00M | 20.37M | 35.63M | 45.57M |
Cash Flow | ||||||
| Free Cash Flow | -10.05M | -9.76M | -1.31M | -11.88M | -12.10M | -4.42M |
| Operating Cash Flow | -10.05M | -9.76M | -1.22M | -11.87M | -11.97M | -4.41M |
| Investing Cash Flow | -3.13M | 5.89M | 2.45M | 13.08M | 14.29M | -43.78M |
| Financing Cash Flow | 14.84M | 2.87M | 209.34K | 404.57K | -2.13M | 26.92M |
Lipocine Technical Analysis
Negative
2.92
Price Trends
3.77
Negative
6.38
Negative
4.75
Negative
Market Momentum
-0.37
Negative
33.80
Neutral
40.42
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LPCN, the sentiment is Negative. The current price of 2.92 is above the 20-day moving average (MA) of 2.31, below the 50-day MA of 3.77, and below the 200-day MA of 4.75, indicating a bearish trend. The MACD of -0.37 indicates Negative momentum. The RSI at 33.80 is Neutral, neither overbought nor oversold. The STOCH value of 40.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LPCN.
Lipocine Risk Analysis
Lipocine disclosed 61 risk factors in its most recent earnings report. Lipocine reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Lipocine Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $10.86M | -1.45 | -317.47% | ― | -100.00% | 59.83% | |
44 Neutral | $18.63M | -3.70 | -66.69% | ― | -45.52% | -94.82% | |
43 Neutral | $4.89M | -1.01 | -79.47% | ― | -100.00% | 62.88% | |
43 Neutral | $23.86M | -0.06 | -83.59% | ― | ― | 19.36% | |
42 Neutral | $91.41M | ― | -53.86% | ― | -20.00% | 75.26% |
* Healthcare Sector Average
LPCN
Lipocine
2.26
-1.26
-35.80%
IBIO
Ibio
1.84
1.02
124.94%
PULM
Pulmatrix
1.34
-5.47
-80.32%
BCDA
BioCardia
0.96
-1.11
-53.86%
SNSE
Sensei Biotherapeutics
17.79
11.88
201.02%
ASBP
Aspire Biopharma Holdings
5.41
-264.59
-98.00%
Lipocine Corporate Events
Business Operations and StrategyProduct-Related Announcements
Lipocine Showcases Phase 3 Data for Postpartum Depression
Positive
May 19, 2026
On May 19, 2026, Lipocine announced that Phase 3 clinical data for LPCN 1154, its oral brexanolone candidate for postpartum depression, were accepted for both oral and poster presentations at the 2026 American Society of Clinical Psychopharmacolog...
Business Operations and Strategy
Lipocine Showcases Pipeline at Virtual Healthcare Conference
Positive
May 18, 2026
On May 18, 2026, Lipocine announced that its management would participate in a fireside chat at A.G.P.’s Annual Virtual Healthcare Company Showcase, scheduled for Wednesday, May 20, 2026, at 3:00 p.m. ET. The appearance underscores the compa...
Business Operations and StrategyRegulatory Filings and Compliance
Lipocine Updates Corporate Presentation for Investor Communications
Neutral
May 7, 2026
Lipocine disclosed that it has updated the corporate presentation it uses in meetings with investors, analysts and other stakeholders. The refreshed materials have been formally filed and are intended to guide ongoing discussions with the financia...
Business Operations and StrategyExecutive/Board Changes
Lipocine Reshapes Board Leadership Amid Strategic Shift
Neutral
Apr 21, 2026
On April 16, 2026, Lipocine Inc. announced that Spyros Papapetropoulos resigned from the Board of Directors, effective immediately, stepping down as Chairman, Lead Independent Director, and member of the compensation committee after serving since ...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Lipocine weighs path after LPCN 1154 Phase 3 miss
Negative
Apr 2, 2026
On April 2, 2026, Lipocine reported topline results from a Phase 3 placebo-controlled trial of LPCN 1154, an oral formulation of brexanolone for postpartum depression, in 90 patients. The study did not meet its primary endpoint, as LPCN 1154 faile...
Business Operations and StrategyRegulatory Filings and Compliance
Lipocine Updates Investor Presentation to Refine Market Messaging
Neutral
Apr 2, 2026
Lipocine has updated the corporate presentation it uses in meetings with investors, analysts and other stakeholders. The refreshed materials have been formally filed and are now available as part of the company’s investor communications reso...
Private Placements and FinancingRegulatory Filings and Compliance
Lipocine Files Prospectus to Enable $50M Stock Offering
Neutral
Mar 4, 2026
On April 26, 2024, Lipocine Inc. entered into a sales agreement with A.G.P./Alliance Global Partners to offer and sell shares of its common stock from time to time through the sales agent. On February 26, 2026, the company filed a prospectus suppl...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.